News & Updates

TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas

15 Mar 2023

Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.

TKI therapy may improve survival in metastatic pheochromocytomas/paragangliomas

15 Mar 2023

Sleep disturbances may drive dementia risk

15 Mar 2023

Individuals who have trouble falling asleep and who use sleep medications are at increased risk of dementia, as reported in a study.

Sleep disturbances may drive dementia risk

15 Mar 2023

Add-on evolocumab improves plaque characteristics in statin-treated CAD patients

15 Mar 2023 by

In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.

Add-on evolocumab improves plaque characteristics in statin-treated CAD patients

15 Mar 2023

NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC

15 Mar 2023 by

In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.

NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC

15 Mar 2023

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

15 Mar 2023

Using methylphenidate and a selective serotonin reuptake inhibitor (SSRI) together does not appear to pose any significant risk, with both agents having been shown to be safe in adolescent patients with attention deficit-hyperactivity disorder (ADHD) and depression, according to a new-user cohort study.

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

15 Mar 2023

Lanadelumab reduces HAE attacks in children

15 Mar 2023 by

Treatment with lanadelumab given every 2 or 4 weeks (Q2W or Q4W dosing) reduces the frequency of attacks in patients aged 2 to <12 years with hereditary angioedema (HAE), according to the SPRING study presented at AAAAI 2023.

Lanadelumab reduces HAE attacks in children

15 Mar 2023

Real-world use affirms benefits of upadacitinib for inflammatory bowel disease

14 Mar 2023

The use of the novel selective JAK-1 inhibitor upadacitinib appears to result in rapid symptom improvements in patients with difficult-to-treat ulcerative colitis or Crohn’s disease, including those who have prior exposure to tofacitinib, according to real-world data.

Real-world use affirms benefits of upadacitinib for inflammatory bowel disease

14 Mar 2023

Looking on the bright side helps with poststroke recovery

14 Mar 2023 by

When it comes to functional recovery after stroke, the adage “always look on the bright side” appears to be true, with a recent study providing evidence that optimism is associated with better recovery.